Jaguar Health's Crofelemer Shows Promising Results for Chronic Diarrhea

Jaguar Health, Inc. (NASDAQ:JAGX) announced positive outcomes from two independent studies of crofelemer, Napo Pharmaceuticals' novel drug, for managing chronic refractory diarrhea. Results will be presented at the American College of Gastroenterology Annual Scientific Meeting in October 2024.

The first study, led by Dr. Judy Nee at Beth Israel Deaconess Medical Center, showed that crofelemer significantly improved stool consistency and reduced abdominal pain in patients with functional diarrhea. Notably, the drug did not cause constipation.

The second study, led by Dr. Brooks D. Cash at the University of Texas Health Science Center, found that nearly 60% of patients with chronic idiopathic diarrhea experienced symptom relief from crofelemer. This pilot study suggests the need for larger trials to further validate these findings.

Functional diarrhea affects patients for over six months without effective treatments. Chronic idiopathic diarrhea impacts 3-5% of people in developed countries, significantly reducing quality of life and adding economic burdens.

Crofelemer, derived from the Croton lechleri tree, is the only FDA-approved drug under botanical guidelines, highlighting its unique plant-based origin.